About
Biomea Fusion, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 27 2026
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Mar 31 2026
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Mar 24 2026
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Mar 14 2026
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Jan 12 2026
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Recent Videos

Dr. Biomea | Episode 3: What Does Nature Say About Your Findings?
Apr 23, 2026

Dr. Biomea | Episode 4: What is Menin?
Apr 23, 2026

Dr. Biomea | Episode 2: What is the Root Cause of Diabetes?
Apr 23, 2026

Dr. Biomea | Episode 1: What Is Diabetes?
Apr 23, 2026
Google Übersetzer